Kamada
Plasma-derived Protein Therapeutics
StartupKamada is a Beit Kama-based startup in the Health Tech & Life Sciences sector, established in 1990. Plasma-derived Protein Therapeutics. The company has raised a total of $150M across 7 funding rounds, currently at the Public stage. Kamada was founded by David Tsur. Key investors include FIMI Opportunity Funds, Hercules Capital, Inc.. The company has 201-500 employees. Core technologies: Biologicals.
With $150M in total funding, Kamada is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released. The company holds 1 patent.
- StagePublic
- ProductReleased
- ModelB2B
- Employees201-500
- HQBeit Kama
- DistrictSouth District
- Last Round$60M
- FIMI Opportunity FundsLead
- Hercules Capital, Inc.
David TsurCo-founder & Owner
158 articles covered by sources including finance.yahoo.com,
en.globes.co.il,
www.kamada.com,
www.globenewswire.com,
www.prnewswire.com.
What does Kamada do?
Kamada is a plasma-derived protein therapeutics company with a commercial product portfolio and a late-stage clinical pipeline. The company uses its proprietary platform technology and expertise for the extraction and purification of proteins from human plasma. The company has two FDA-approved products: GLASSIA, intravenous plasma-derived Alpha-1 Antitrypsin (AAT) for the treatment of AAT deficiency, marketed in the United States through a strategic partnership with Shire Plc; and KEDRAB, a rabies immune globulin (human) product distributed in the United States by Kedrion. Kamada also sells an additional four plasma-derived pharmaceutical products in approximately 20 markets. Kamada has products in late-stage clinical development, including an inhaled formulation of AAT and intravenous AAT for the treatment of type 1 diabetes and GvHD and the prevention of lung transplant rejection.
How much funding has Kamada raised?
Kamada has raised $150M in total funding across 7 rounds. The company is currently at the Public stage. Key investors include FIMI Opportunity Funds, Hercules Capital, Inc..
Who founded Kamada?
Kamada was founded in 1990 by David Tsur (Co-founder & Owner).
What sector is Kamada in?
Kamada operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Biomaterials & Tissue Engineering, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Pharmaceuticals.
Where is Kamada located?
Kamada is based in Beit Kama, Israel, South District.